Caladrius unveils positive results of CLBS16 in CMD treatment
Category: #health  By Pankaj Singh  Date: 2019-11-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Caladrius unveils positive results of CLBS16 in CMD treatment
  • The data shows a major statistical improvement in coronary flow reserve
     
  • Single-use CLBS16 can reportedly improve heart function and symptoms

Caladrius Biosciences, Inc., a biopharmaceutical firm mainly focused on the development of the treatments for certain cardiovascular diseases, with the help of researchers from Mayo Clinic in Rochester, Minnesota, the Christ Hospital in Cincinnati and Los Angeles’ Cedars-Sinai, recently presented results from the autologous CD34+ cell therapy, also known as CLBS16, of Caladrius’s ESCaPE-CMD trial, at the American Heart Association Scientific Sessions 2019.

The results presented were for patients who have finished the six-month follow-up date while the remaining results from the other patients will be presented by the end of 2019. The data depicted a major statistical improvement in the coronary flow reserve in relation to symptom relief in patients suffering from coronary microvascular dysfunction after they were injected with CLBS16 intracoronary injection.

Caladrius’ CEO and President, David J. Mazzo, Ph.D. stated that CLB16 represents a probable breakthrough for CMD treatment, a condition that millions suffer from in the U.S. and has an excessive effect on women. The trial is the first time when therapy has exhibited its capability of increasing coronary flow reserve and possibly reverse CMD after one dose.

Apparently, the ESCaPE-CMD trial is essentially an interventional study intended to analyze the effect of autologous CD34+ cell therapy (CLBS16) of Caladrius on the symptoms as well as indicators of CDM while also being able to analyze the tolerance for the treatment. The trial had reportedly finished the enrollment of 20 patients targeted in May 2019. Every patient was given a single infusion of GCSF-mobilized CD34+ cells which were formulated as CLBS16.

Chief Medical officer, Caladrius, Douglas W. Losordo, M.D., FACC, FAHA, commented that patients suffering from CMD tend to be frustrated and in despair often due to unresolved symptoms after they have exhausted every therapy. The data indicate that CD34+ repair cells will be able to provide strong improvements in the symptoms and reduce any risks of dangerous cardiovascular outcomes.

 

Source Credits- https://www.caladrius.com/press-release/caladrius-biosciences-reports-positive-results-for-clbs16-from-the-escape-cmd-trial-at-american-heart-association-scientific-sessions-2019/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Toyota and ENEOS team up to develop hydrogen fuel-cell system in Japan
Toyota and ENEOS team up to develop hydrogen fuel-cell system in Japan
By Pankaj Singh

Japanese automotive giant, Toyota has reportedly tapped Japanese oil & energy corporation, ENEOS, to explore the field of hydrogen-based power to help with the development of a hydrogen fuel-cell system that would power Woven City, Japan’s ...

KPI Global secures 12.5 MW captive solar project from Anupam Rasayan
KPI Global secures 12.5 MW captive solar project from Anupam Rasayan
By Pankaj Singh

Gujarats leading solar power generating company, KPI Global, has recently announced receiving an order for building a 12.5 megawatts solar project under the captive power producer capacity from Surat-headquartered Anupam Rasayan India. It has been r...

Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
By Pankaj Singh

Adverum Biotechnologies, a California based biotech company, has reportedly announced new clinical data from the OPTIC Phase 1 with dose ranging clinical stage trial of gene therapy intravitreal injection namely ADVM-022. The OPTIC trial has enrolle...